Also known as: IGH/MYC FISH t(8;14) FISH« Back to test list
Gene fusions involving the IGH gene at 14q32 and MYC at 8q24 are common in Burkitt lymphoma. They can also occur in other B-cell non-Hodgkin lymphomas, for example, diffuse large B-cell lymphoma (DLBCL). Less commonly, MYC can be fused with other gene partners, such as IGK and IGL.
Such gene fusions have diagnostic and prognostic implications.
Presence of an IGH-MYC gene fusion can be useful in diagnosing Burkitt lymphoma. In association with BCL2 and BLC6 gene fusions (see ‘double/triple hit lymphoma panel’), this fusion can also indicate prognosis in B-cell lymphoma with features intermediate between DLBCL and Burkitt lymphoma.
This is an assay for non-heritable mutations. It does not raise issues of ethics or consent that are different from most other investigations ordered in the routine care of a patient.
Fluorescent in situ hybridisation (FISH) analysis, using probes to identify fusion of IGH with MYC, due to a t(8;14)(q24;q32) translocation.
This test is usually requested by a haematologist or oncologist.
0.5 mL bone marrow in transport media, or 5-10 mL blood in lithium heparin.
To help ensure the quality of the test, a genetic test should be done with a dedicated sample whenever possible i.e. a sample collected specifically for that test rather than a sample that is used for multiple tests.
We also recommend that the patient or another adult check the labelling of request forms and sample tubes.